ReviewFrontiers in neurology2026
Neuroimmunological overlap syndromes in optic neuritis, myelitis, and connective tissue diseases.
Review in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuroimmunological overlap syndromes encompassing optic neuritis, myelitis, and connective tissue disorders (CTDs) represent an emerging autoimmune spectrum at the intersection of neurology, immunology, and rheumatology. These conditions share convergent pathogenic mechanisms including blood-brain barrier dysfunction, cytokine dysregulation, complement activation, and adaptive immune imbalance, yet are often managed as discrete entities despite overlapping clinical features. Method: A narrative review was conducted across PubMed, Web of Science, and Google Scholar (January 2014-March 2026) using keywords related to NMOSD, MOGAD, MS, optic neuritis, myelitis, and CTDs. Preference was given to systematic reviews, meta-analyses, randomized controlled trials, and large observational cohort studies. Outcomes: Shared pathogenic mechanisms include BBB disruption, pro-inflammatory cytokines (IL-6, IL-17, TNF- Conclusion: Neuroimmunological overlap syndromes should be conceptualized as a unified neuroimmune continuum rather than discrete diseases. Priority research includes biomarker validation, head-to-head comparative cohorts, and randomized trials for MOGAD and CTD-associated neuroinflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.